source · text/markdown
source_ccd3ed00c5084c62
sha256 d6aeb31f26fbddaf3568ae4151c9119b0b69a26c00206cc6b2cbf331698b1550
by researka:v2 · 2026-05-28 12:43:30.580034+04:00
This synthesis tests the thesis that evidence for ARBs longevity is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Angiotensin receptor blockers (ARBs) and their neprilysin-inhibitor combinations exert pleiotropic effects on cardiovascular, renal, and metabolic pathways that are mechanistically linked to aging biology, yet whether these agents extend human lifespan or healthspan remains unresolved. This synthesis was generated through a structured, AI-assisted evidence review of 71 curated reference papers, with each claim anchored to specific source-traced data and all tensions between outcome classes documented in an audit trail. In sum, the weight of evidence supports ARBs—particularly neprilysin-inhibitor combinations—as cardioprotective agents with plausible but unproven longevity benefits; the anti-aging case as currently constituted is incomplete because the cross-study disagreements across outcome classes and the absence of dedicated lifespan RCTs leave the boundary conditions undefined.
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "1a588040-bbc1-45ea-ba33-3ce4c71f87f6",
"title": "Research Synthesis: ARB Longevity \u2014 full paper"
}